Alginates in therapy for gastroesophageal reflux disease


Cite item

Full Text

Abstract

This article presents evidence of the prevalence of gastroesophageal reflux disease (GERD) and highlights its main treatment options. Among its medications, particular emphasis is laid on alginates and their main mechanisms of action are described. There is information on the efficacy of alginates, including the alginate-antacid Gaviscon Double Action, in treating GERD. Recommendations for how to administer these drugs are given.

About the authors

V G Avdeev

References

  1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastro-esophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-1920.
  2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-esophageal reflux disease: a systematic review. Gut. 2005;54(5):710-717.
  3. Лазебник Л.Б., Машарова А.А., Бордин Д.С., Васильев Ю.В., Ткаченко Е.И., Абдулхаков Р.А., Бутов М.А., Еремина Е.Ю., Зинчук Л.И., Цуканов В.В. Результаты Многоцентрового исследования «Эпидемиология Гастроэзофагеальной Рефлюксной болезни в России» (МЭГРЕ). Терапевтический архив. 2011;1:45-50.
  4. Frieling T. Antireflux therapy — more than acid reduction. Internist (Berl). 2004;45:1364-1369.
  5. Ивашкин В.Л., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике. Русский медицинский журнал. 2003;11(2):43-48.
  6. Маев И.В., Трухманов А.С. Лекарственная терапия неэрозивной рефлюксной болезни. Русский медицинский журнал. 2004;12(24):1402-1409.3.
  7. Wolfe MM, Lowe RC. Investing in the Future of GERD. J Clin Gastroenterol. 2007;41:209.
  8. Drossman D. Rome III: The functional gastrointestinal disorders. McLean V.A.: Degnon Associates, Inc.; 2006:369-418.
  9. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. РЖГГК. 2011;ХХI(4):4-13.
  10. Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-esophageal reflux disease therapies. Aliment Pharmacol Ther. 2006;25(2):143-153.
  11. Исаков В.А., Морозов С.В., Ставраки Е. С., Комаров Р. М. Анализ распространенности изжоги: национальное эпидемиологическое исследование взрослого городского населения (АРИАДНА). Экспериментальная и клиническая гастроэнтерология. 2008;1:20-29:(Шифр Э647817/2008/1)
  12. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK. New algorithm for the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2008;27(3):249-256.
  13. Tytgat G, Headings R Muller-Lissner S Kamm MA, Schölmerich J, Berstad A, Fried M, Chaussade S, Jewell D, Briggs A. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther. 2003;18(3):291-301.
  14. Елохина Т.Б., Тютюнник В.Л. Гастроэзофагеальная рефлюксная болезнь при беременности. РМЖ. 2008;16(19): 1243–1247.
  15. Richter JE, Kahrilas PJ, Johanson J Maton P, Breiter J.HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/?term=Breiter JR[Author]&cauthor=true&cauthor_uid=11280530”R., Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96 (3):656-665.
  16. Madanick RD, Katz PO. GERD and pregnancy. Practical Gastroenterology. 2006;30:30-39
  17. Lang GD, Dougall A. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy. Br J Clin Pract. 1990;66:48-51.
  18. Uzan M, Uzan S, Surean C, Richard-Berthe C. Heartburn and regurgitation in pregnancy, efficacy and innocuousness of treatment with Gaviscon suspension. Rev Fr Gynecol Obstet. 1988;83:569-572.
  19. Lindow SW, Regnell P Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. International J of Clinical Practice. 2003;57(3):175-179.
  20. Dean BB, Gano Jr A D, Knight K Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2(8):656-664.
  21. Liker HR, Ducrotter P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27:62-67.
  22. Mastronarde JG, Anthonisen NR, Castro M. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360:1487-1499.
  23. McQuaid KR, Laine L. Купирование изжоги с помощью ингибиторов протонной помпы: систематический обзор и метаанализ клинических испытаний. Клиническая гастроэнтерология и гепатология. (Русское издание). 2008;1(3):184-192.
  24. Strugala V, Dettmar PW, Sarratt K, Sykes J, Berry P, Thomas E. A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med Res. 2010;38:449-457.
  25. Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, Nakata H, Katoh T, Miyamoto M, Tanaka S. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5) :373-380.
  26. Kapadia CJ, Mane VB. Raft-forming agents: antireflux formulations. Drug Dev Ind Pharm. 2007;33(12):1350-1361.
  27. Лазебник Л.Б., Бордин Д.С., Машарова А.А., Джулай Г.С., Бутов М.А., Абдулхаков Р.А., Еремина Е.Ю., Тарасова Л.В., Сафонова О.В., Фирсова Л.Д., Кожурина Т.С. Восстановление качества жизни устранением и предотвращением изжоги альгинатом: результаты многоцентрового исследования «ВИА АПИА». Экспериментальная и клиническая гастроэнтерология. 2010;6:70-76.
  28. Oliver KL, Davies GJ. Heartburn: influence of diet and lifestyle. Nutr Food Sci. 2008;38:548-554.
  29. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001;121(4):775-783.
  30. Beaumont H, Bennink R J, de Jong J, Boeckxstaens GE. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut. 2010;59:441-451.
  31. Pandolfino J, Ghosh S, Zhang Q, Han A, Kahrilas PJ. Upper sphincter function during transient lower esophageal sphincter relaxation (tLOSR): it is mainly about microburps. Neurogastroenterol Motil. 2007;19:203-210
  32. Sgouros S, Mpakos D, Rodias M, Vassiliades K, Karakoidas C, Andrikopoulos E, Stefanidis G, Mantides A. Prevalence and axial length of hiatus hernia in patients, with nonerosive reflux disease: a prospective study. J Clin Gastroenterol. 2007;41(9):814-818.
  33. Scheffer R, Bredenoord A, Hebbard G, Smout AJ, SamHYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/?term=Samsom M[Author]&cauthor=true&cauthor_uid=20105278”som M. Effect of proximal gastric volume on hiatal hernia. Neurogastroenterol Motil. 2010;22(5):552-556.
  34. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther. 2002;16(5):881-886.
  35. Vo L, Simonian H, Doma S, Fisher RS, Parkman HP. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-esophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2005;21(11):1321-1330.
  36. Morgan D, Pandolfino J. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastroesophageal reflux disease — comparator study of esomeprazole, lansoprazole, and pantoprazole. Aliment Pharmacol Ther. 2010;32(2):200-208.
  37. Hampson F, Farndale A, Strugala V et al. Alginate rafts and their characterization. Int J Pharm. 2005;294:137-147.
  38. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14:669–690.
  39. Kwiatek M, Roman S, Fareeduddin A, PandolfHYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/?term=Pandolfino JE[Author]&cauthor=true&cauthor_uid=21535446”ino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59-66.
  40. Rohof W, Bennink R, Boeckxstaens G. Effect of PPIs on the size, position and acidity of the postprandial acid pocket. Gastroenterology. 2012;142(5):92.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies